vena cava syndrome
Recently Published Documents


TOTAL DOCUMENTS

1268
(FIVE YEARS 222)

H-INDEX

43
(FIVE YEARS 2)

2022 ◽  
Vol 83 ◽  
pp. 16-20
Author(s):  
Nicholas A. Schreiter ◽  
John Swietlik ◽  
Michael Woods ◽  
Mark Kleedehn

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 158
Author(s):  
Simona Manole ◽  
Roxana Pintican ◽  
Emanuel Palade ◽  
Maria Magdalena Duma ◽  
Alexandra Dadarlat-Pop ◽  
...  

We report a case of a 52-year-old woman who was referred to our institution with a superior vena cava syndrome and was investigated through echocardiography, CT and MRI revealing a well-defined, encapsulated pericardial mass. The pathology, correlated with the immunohistochemical analysis, concluded it was an extremely rare primary pericardial synovial sarcoma. The patient underwent surgery and chemotherapy with a 16-month disease-free survival and passed away after a contralateral aggressive relapse. Moreover, we discuss the role of each imaging modality together with their pericardial synovial sarcoma reported features.


Author(s):  
R. Rajavardhan ◽  
Rajesh Mohan Shetty ◽  
Nithya Chowrira Achaiah ◽  
Manjunath Thimmappa ◽  
Arun Veeram Reddy

Cureus ◽  
2022 ◽  
Author(s):  
Vasileios Patriarcheas ◽  
Maria Grammoustianou ◽  
Nikolaos Ptohis ◽  
Ioanna Thanou ◽  
Minas Kostis ◽  
...  

2022 ◽  
pp. 1082-1089
Author(s):  
Julie Berman
Keyword(s):  

2021 ◽  
Vol 50 (1) ◽  
pp. 557-557
Author(s):  
Yamini Patel ◽  
Mohammad Asim Amjad ◽  
Viren Raheja ◽  
Navharsh Sekhon ◽  
Pius Ochieng

2021 ◽  
Vol 24 (6) ◽  
pp. E952-E957
Author(s):  
Shoujin Cao ◽  
Yinghua Zou ◽  
Tianshi Lyu ◽  
Zeyang Fan ◽  
Haitao Guan ◽  
...  

Background: Patients with malignant superior vena cava syndrome (SVCS) usually require urgent treatments due to a high potential risk of early mortality. Stent implantation can rapidly improve the symptoms of SVCS, which may be beneficial to subsequent anti-tumor therapy. The aim of the study was to evaluate the clinical outcomes of stent graft implantation for the treatment of superior vena cava (SVC) obstruction caused by non-small cell lung carcinoma (NSCLC) with acute post-stenting occlusion. Methods: Between October 2014 and December 2019, 16 patients were selected for stent graft implantation. Technical success and clinical efficacy were assessed. Stent patency and patient survival rates, as well as the complications were analyzed. Results: There were 17 stent grafts implanted in 16 patients. The technical success was 100%. The residual stenosis after initial implantation was 64.0 ± 9.0%. The stent expanded to an optimal size in 5.5 ± 2.2 days after the initial deployment. Migration occurred when deploying of the stent graft in one patient; this stent graft was successfully stabilized by a second one. No other complications related to the procedure were found except one migration. At 1, 3, 6, 9 and 12 months, the cumulative survival rates were 100%, 75%, 56%, 19% and 0%, respectively. The mean OS was 173 days. The median survival was 166 days. Conclusions: Stent graft can be safely used in patients with SVC obstruction with a good long-term patency rate.


Sign in / Sign up

Export Citation Format

Share Document